← Back to Search

Drug Resistance Research for Osteosarcoma

N/A
Waitlist Available
Led By John Healey, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a presumed or known diagnosis of a primary or secondary bone cancer or other solid tumor who are having or have had a biopsy or surgery to remove tumor for diagnostic or therapeutic reasons. No tumors will be obtained solely for research purposes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how different drugs affect tumors and why some tumors develop high pressure, which can affect how well drugs work. Blood samples will be taken to help predict the behavior of different types of tumors.

Who is the study for?
This trial is for individuals with a presumed or confirmed diagnosis of bone cancer (osteosarcoma) or other solid tumors who are undergoing biopsy or surgery. It's open to adults and minors; adults must consent, while minors give assent and have parental consent.
What is being tested?
The study aims to understand how osteogenic sarcoma and other solid tumors react to drug therapies by examining tumor tissue and blood samples. Researchers will look into why some tumors resist treatment and the impact of internal tumor pressure on drug effectiveness.
What are the potential side effects?
Since this trial involves tissue procurement rather than testing a new medication, there aren't direct side effects from drugs being studied. However, typical risks associated with biopsies or surgeries may apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have or had a biopsy or surgery for bone or solid tumor cancer diagnosis or treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkOTHER
250 Previous Clinical Trials
60,573 Total Patients Enrolled
Weill Medical College of Cornell UniversityOTHER
1,091 Previous Clinical Trials
1,154,600 Total Patients Enrolled
Columbia UniversityOTHER
1,492 Previous Clinical Trials
2,664,095 Total Patients Enrolled
Rockefeller UniversityOTHER
160 Previous Clinical Trials
15,763 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,976 Previous Clinical Trials
598,737 Total Patients Enrolled
12 Trials studying Osteosarcoma
544 Patients Enrolled for Osteosarcoma
John Healey, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
329 Total Patients Enrolled
~16 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top